Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of one of the following: * Relapsed or refractory acute myeloid leukemia (AML); patients with acute promyelocytic leukemia t(15;17) must have failed tretinoin (ATRA), arsenic, and gemtuzumab ozogamycin to be eligible (patients should be refractory to all three agents-absence of durable hematologic response or relapse with complete remission \[CR\] duration of less than 6 months) * Relapsed or refractory pre-B- or T-cell acute lymphoblastic leukemia (ALL); patients with Philadelphia chromosome-positive (Ph+) ALL \[t(9;22)\] will be eligible provided that they have failed (intolerance/resistance) at least 2 different tyrosine kinase inhibitors (TKIs) or have a mutation associated with resistance to TKIs (T315I) * Chronic myelogenous leukemia (CML) in accelerated or blastic phase; patients failed (resistance/intolerance) at least 2 different TKIs or have a mutation associated with resistance to TKIs (T315I) * Chronic myelomonocytic leukemia-2 (CMML-2) defined as having \> 10% blasts (including promonocytes) in the bone marrow or \> 5-19% blasts (including promonocytes) in the peripheral blood * AML arising in the setting of antecedent myelodysplasia (MDS) or myeloproliferative disorder (MPD) * Therapy-related AML * Untreated AML in adults 60 years of age and older who are not candidates for induction chemotherapy due to poor-risk features including adverse cytogenetics or molecular markers …